INTRODUCTION
• Venous thromboembolism (VTE) is a major cause of morbidity and mortality worldwide and its treatment costs are considerable and increasing 1 .
• According to EINSTEIN trials, rivaroxaban is non-inferior to enoxaparin followed by vitamin K antagonist (VKA) regarding recurrent VTE in patients with deep vein thrombosis (DVT) 2 and in patients with pulmonary embolism (PE) 3 . Current American College of Physicians (ACP) guidelines recommend either parenteral anticoagulant therapy or anticoagulation with rivaroxaban for acute VTE treatment 4 .
• In EINSTEIN randomized trials, rivaroxaban led to fewer days hospitalized compared with enoxaparin/VKA 5 .
• There are scarce data on the costs related to VTE patients in Brazil. The purpose of this research is to provide a cost-minimization analysis (CMA) of rivaroxaban in comparison to enoxaparin/VKA for the treatment of VTE under the Brazilian private healthcare system perspective.
METHODS

Economic model
• CMA was chosen once the EINSTEIN program showed that rivaroxaban is non-inferior to enoxaparin/VKA regarding efficacy for treatment of VTE, being possible to consider that there is no difference in recurrent VTE primary outcome.
• The EINSTEIN program also showed that patients in treatment with rivaroxaban had a mean length of stay lower than with enoxaparin + VKA as well as lower risk of major bleeding in patients with PE. Costs considered in the model are represented in Figure 1 .
• Perspective was from the Brazilian private healthcare system and time horizon was one year.
Resource use and costing • Costs considered in the model were those reimbursed by private payers in Brazil, and included: hospitalization costs (including drugs and tests used in index and in recurrent events and costs related to the management of complications) and monitoring costs (including post-discharge visits and tests).
• Inputs were obtained from literature and expert panel.
• It was assumed the same treatment duration distribution in 3, 6 and 12 months for both groups (rivaroxaban or enoxaparin + warfarin), in accordance to EINSTEIN program findings.
• Main inputs in the model were based on EINSTEIN program results, which were adverse events rates, need for hospitalization due the index event, recurrence rate, mean length of stay in the hospital, and treatment and follow up duration.
• An expert's panel with seven specialists was conducted to obtain resource utilization. Experts were asked about their practice in hospitalization and outpatient management of VTE.
• Based on the consensus of resource utilization, costs were obtained by a micro-costing approach.
• Cost sources were publicly available reference tables such as CBHPM and SIMPRO.
• Costs were expressed in 2015 prices and exchange rate used was 1.00USD=4.00BRL.
Sensitivity Analysis
• A deterministic univariate sensitivity analysis was developed to test the robustness of the model. • Parameters tested were 100% increase in surgeries cost, cost of enoxaparin (±14.3%), days hospitalized in both groups (±20%), rivaroxaban cost (±7%) and hospitalization and outpatient costs (±15%). 
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ABSTRACT LIMITATIONS
• We assumed 100% adherence to therapy and to monitoring of patients.
• Length of stay, which was responsible for a significant proportion of costs, was extrapolated from a controlled trial (although it was left to the judgment of the attending physician).
CONCLUSIONS
• Hospitalization costs represent the greatest share of the total cost in acute VTE patients.
• Rivaroxaban constitutes a single-drug oral regimen that can lead to reduction in VTE treatment costs in comparison with enoxaparin/ VKA under the Brazilian private healthcare system perspective.
RESULTS
Base case results • Rivaroxaban use was cost saving in comparison with enoxaparin + warfarin in the treatment of VTE.
• Estimated total cost of treatment for one patient with VTE is $1,559 with rivaroxaban and $2,007 with enoxaparin + warfarin (Figure 2 ). • The use of rivaroxaban would cause a cost reduction of 22% in VTE treatment, 32.5% in DTV treatment and 19% in PE treatment.
Sensitivity Analysis
• All results obtained with the sensitivity analysis remained cost saving (Figure 3 ). Table 1 shows model mean costs, weighted by the percentage of hospitalization/outpatient treatment, recurrence and adverse events. Cost-minimization analysis of rivaroxaban in comparison to enoxaparin plus warfarin for the treatment of Venous Thromboembolism (VTE) under the private Healthcare system perspective PCV119
